1. Vimkunya, a single-dose vaccine for chikungunya virus, demonstrated efficacy in a clinical trial.
2. Rapid and durable immune responses were observed across different age groups.
3. The vaccine was well-tolerated with mostly mild or moderate side effects.
4. The study confirmed consistent performance across production lots.
5. Participants with preexisting immunity showed stronger responses.
6. The vaccine is a potential option for individuals aged 12 years and older.
7. No safety concerns were identified except for a rare unrelated birth defect.
8. The researchers plan to evaluate real-world effectiveness in endemic regions.

Source: The Lancet